HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness Company offering premium probiotic supplements and products containing CBD, commends the Hemp Access and Consumer Safety Act (the “Act” or “Bill”), filed by Senators Ron Wyden (D- Ore.), Rand Paul (R-Ky.) and Jeff Merkley (D-Ore.) that aims to add hemp, hemp-derived cannabidiol, or a substance containing any other ingredient derived from hemp to the definition of dietary supplement according to the Federal Food, Drug, and Cosmetic Act and would remove certain restrictions that have blocked the emergence of legal consumable hemp products in the United States.

HempFusion has been a longstanding member of the US Hemp Roundtable which is a major advocate for the Bill.

“HempFusion is prepared for both GRAS (Generally Recognized as Safe) and NDIN (New Dietary Ingredient Notification) which separates us from the vast majority of CBD brands on the market today,” stated Dr. Jason Mitchell, HempFusion’s Co-Founder and Chief Executive Officer. “We proudly endorse and commend The Hemp Access and Consumer Safety Act and thank Senators Wyden, Paul and Merkley for their bipartisan support. A major component of our strategic business plan has been to prepare for this day and now we are finally at the door of what will open up the CBD industry for those brands that can properly adhere to FDA’s requirements,” continued Dr. Mitchell.

“While the Senate bill is more comprehensive than the previously introduced House bill H.R. 841, passage of either will provide a vast and very important boost to the hemp industry, benefitting farmers, producers, manufacturers, small and large retailers and, most importantly, consumers,” stated Ola Lessard, HempFusion’s Chief Marketing Officer. “The lack of clear regulation for the past several years has had devastating economic impact across many sectors. It’s also allowed fly-by-night companies to thrive, selling products that don’t meet label claims, aren’t manufactured properly, and – in some cases – are actually dangerous to consumers,” continued Lessard.

ABOUT HEMPFUSION

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com.

Follow HempFusion on Twitter, Facebook and Instagram and Probulin on Twitter, Facebook and Instagram.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements“) that relate to HempFusion’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the Company’s strategic business plan and the Company’s other plans, focus and objectives.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in the annual information form of the Company dated March 31, 2021 and available under the Company’s profile on SEDAR at www.sedar.com. HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.